Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:CTOR NASDAQ:IMA NASDAQ:OKYO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.40$0.45$0.01▼$3.42$16.11M-1.8842,231 shs100 shsCTORCitius Oncology$0.66-3.7%$0.82$0.49▼$6.19$63.74M3.4160,265 shs29,148 shsIMAImageneBio$5.94-1.0%$5.74$3.94▼$18.00$63.93M0.7214,617 shs13,747 shsOKYOOKYO Pharma$1.54-0.6%$1.61$1.42▼$3.35$62.86M0.0257,314 shs87,186 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%+1.18%-21.00%-55.46%-73.13%CTORCitius Oncology-3.72%-1.45%-23.26%+28.96%-76.09%IMAImageneBio-1.00%-1.00%+2.06%+18.80%-63.06%OKYOOKYO Pharma-0.65%-3.14%-9.94%+0.65%-37.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.40$0.45$0.01▼$3.42$16.11M-1.8842,231 shs100 shsCTORCitius Oncology$0.66-3.7%$0.82$0.49▼$6.19$63.74M3.4160,265 shs29,148 shsIMAImageneBio$5.94-1.0%$5.74$3.94▼$18.00$63.93M0.7214,617 shs13,747 shsOKYOOKYO Pharma$1.54-0.6%$1.61$1.42▼$3.35$62.86M0.0257,314 shs87,186 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%+1.18%-21.00%-55.46%-73.13%CTORCitius Oncology-3.72%-1.45%-23.26%+28.96%-76.09%IMAImageneBio-1.00%-1.00%+2.06%+18.80%-63.06%OKYOOKYO Pharma-0.65%-3.14%-9.94%+0.65%-37.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/ACTORCitius Oncology 2.33Hold$6.00809.09% UpsideIMAImageneBio 2.00Hold$26.50346.13% UpsideOKYOOKYO Pharma 2.40Hold$6.33311.26% UpsideCurrent Analyst Ratings BreakdownLatest ANEB, OKYO, IMA, and CTOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026CTORCitius Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/11/2026IMAImageneBio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform4/21/2026OKYOOKYO Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/ACTORCitius OncologyN/AN/AN/AN/A$0.54 per shareN/AIMAImageneBio$800K79.08N/AN/A$11.91 per share0.50OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%N/ACTORCitius Oncology-$24.76M-$0.47N/AN/AN/AN/A-99.47%-42.16%8/18/2026 (Estimated)IMAImageneBio-$45.35M-$5.79N/AN/AN/AN/A-38.96%-34.60%N/AOKYOOKYO Pharma-$4.71MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)Latest ANEB, OKYO, IMA, and CTOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026CTORCitius Oncology-$0.01-$0.27-$0.26-$0.27$7.00 million$1.67 million5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A6.246.24CTORCitius Oncology0.110.500.12IMAImageneBioN/A18.3918.39OKYOOKYO PharmaN/A0.58N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%CTORCitius Oncology70.52%IMAImageneBio75.00%OKYOOKYO Pharma2.97%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%CTORCitius Oncology9.80%IMAImageneBio2.22%OKYOOKYO Pharma40.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableCTORCitius OncologyN/A92.98 million83.87 millionN/AIMAImageneBio7010.65 million10.42 millionNot OptionableOKYOOKYO Pharma740.56 million24.15 millionNot OptionableANEB, OKYO, IMA, and CTOR HeadlinesRecent News About These CompaniesOKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from AnalystsJune 25 at 2:44 AM | americanbankingnews.comOKYO Pharma (NASDAQ:OKYO) Trading Down 1.9% - Should You Sell?June 25 at 2:02 AM | americanbankingnews.comOKYO Pharma And The Small-Cap Eye Care StoryJune 18, 2026 | kalkinemedia.comKOKYO Pharma expands scientific advisory board with cornea expert - ICYMIMay 23, 2026 | proactiveinvestors.comWhat Makes OKYO Pharma (OKYO) a New Buy StockMay 20, 2026 | zacks.comOKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti AppointmentMay 19, 2026 | finance.yahoo.comOKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory BoardMay 19, 2026 | proactiveinvestors.comOKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhDMay 19, 2026 | globenewswire.comOKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in MayApril 29, 2026 | globenewswire.comOKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026April 7, 2026 | finance.yahoo.comOKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentationApril 7, 2026 | proactiveinvestors.comOKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual MeetingApril 7, 2026 | globenewswire.comMost and least shorted healthcare stocks with up to $2B market cap in MarchApril 3, 2026 | msn.comOKYO reports improved quality of life outcomes with urcosimod in phase 2a NCP trialMarch 20, 2026 | ophthalmologytimes.comOOKYO Pharma Announces Chairman and Founder Acquires SharesMarch 19, 2026 | globenewswire.comOKYO Pharma Announces Director Acquires SharesMarch 19, 2026 | globenewswire.comOKYO Pharma Announces Chief Development Officer and Director Acquires SharesMarch 19, 2026 | globenewswire.comFTSE 100 Live: Stocks expected to slump as oil prices soar on Iran counterattacksMarch 19, 2026 | proactiveinvestors.comOKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trialMarch 18, 2026 | proactiveinvestors.comOKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal PainMarch 18, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPlanet Labs: Coming Back Down to EarthBy Chris Markoch | June 8, 2026What to Expect From Q2 Earnings as Tech Strength BroadensBy Thomas Hughes | June 14, 2026AI’s Biggest Bottleneck Could Make These 2 Stocks SoarBy Jeffrey Neal Johnson | May 28, 2026Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?By Sam Quirke | June 6, 2026What's Make of Macy's: Berkshire Hathaway's Latest BuyBy Leo Miller | June 8, 2026ANEB, OKYO, IMA, and CTOR Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$0.40 0.00 (0.00%) As of 06/24/2026 10:18 AM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Citius Oncology NASDAQ:CTOR$0.66 -0.03 (-3.72%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$0.71 +0.05 (+7.58%) As of 06:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.ImageneBio NASDAQ:IMA$5.94 -0.06 (-1.00%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$6.06 +0.12 (+2.02%) As of 06/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.OKYO Pharma NASDAQ:OKYO$1.54 -0.01 (-0.65%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$1.54 +0.00 (+0.32%) As of 06/25/2026 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal MDA Space Targets US Defense Market With $620M Acquisition Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Cerebras Systems, Inc: The Next Rags-to-Riches AI Story? Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
